Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Cutting-Edge Stem Cell Work, California Billions Still Unmatched

This article was originally published in Start Up

Executive Summary

California’s stem cell agency still has nearly two billion dollars to grant. But with recent stem cell breakthroughs slow to translate, will venture backers and drug firms help build the ecosystem California citizens imagined in 2004 when they voted to make the state a beacon for the science?

You may also be interested in...



Aiming For More Deals, Shire Christens Regenerative Medicine Unit

The company hopes its newest division will mirror the growth of its rare disease unit, which was built largely through aggressive business development.

Geron Restructuring Sours Investors As Company Bets On Cancer

The pioneering U.S. biotech will look to partner its five human embryonic stem cell research programs while focusing entirely on two mid-stage cancer assets.

AAVLife: Another Gene Therapy Effort To Treat Friedreich's Ataxia

With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM016193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel